Until recently, manufacturing a genotyping array, especially with primarily custom-content, was prohibitively expensive. The Smokescreen array represents the next generation of targeted arrays, providing both baseline genome-wide content, and enhanced coverage of important regions and pathways specific to a phenotype or group of related phenotypes. The popularity of these similarly-sized arrays can be seen in the Psychiatric Genetics Consortium Infinium PsychArray [60] with 571,054 SNPs (271,406 genome-wide tag SNPs, 276,701 exonic markers, and ~50,000 markers associated with common psychiatric disorders) and the OncoArray Consortium OncoArray-500 K [61] with 499,170 SNPs (275,691 genome-wide tag SNPs and 223,479 cancer specific SNPs). These three arrays offer a core set of markers that provide similar imputation-based genome-wide coverage. Used a procedure similar to Nelson et al. [62], we estimated that the Smokescreen design covers 66 %, 82 %, and 91 % of common variants (MAF ≥ 0.05) in YRI, ASN, and EUR, respectively. The Smokescreen array includes extensive custom content (350,209 markers), focusing on enhancing coverage of gene regions and pathways related to addiction (dependence, drug metabolism, and treatment response), and attributable disease (proliferative,
